

Rationale, Design, and Methodology of the MORCOR-TURK Trial: Predictors of In-hospital MORTality in CORonary Care Patients in Turkey

ABSTRACT

Background: Coronary care units are sophisticated clinics established to reduce deaths due to acute cardiovascular events. Current data on coronary care unit mortality rates and predictors of mortality in Turkey are very limited. The MORTality predictors in CORonary care units in TURKey (MORCOR-TURK) trial was designed to provide information on the mortality rates and predictors in patients followed in coronary care units in Turkey.

Methods: The MORCOR-TURK trial will be a national, observational, multicenter, and noninterventonal study conducted in Turkey. The study population will include coronary care unit patients from 50 centers selected from all regions in Turkey. All consecutive patients admitted to coronary care units with cardiovascular diagnoses between 1 and 30 September 2022 will be prospectively enrolled. All data will be collected at one point in time, and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT05296694).

In the first step of the study, admission diagnoses, demographic characteristics, basic clinical and laboratory data, and in-hospital management will be assessed. At the end of the first step, the predictors and rates of in-hospital mortality will be documented. The second step will be in cohort design, and discharged patients will be followed up till 1 year. Predictors of short- and long-term mortality will be assessed. Moreover, a new coronary care unit mortality score will be generated with data acquired from this cohort.

Results: The short-term outcomes of the study are planned to be shared by early 2023.

Conclusion: The MORCOR-TURK trial will be the largest and most comprehensive study in Turkey evaluating the rates and predictors of in-hospital mortality of patients admitted to coronary care units.

Keywords: Cardiovascular mortality, coronary care unit, in-hospital mortality, mortality predictors, mortality scoring system

INTRODUCTION

Coronary care unit (CCU) was first established in the 1960s to reduce cardiovascular (CV) mortality which is the leading cause of death worldwide. After Killip and Kimball showed a 20% mortality reduction in acute myocardial infarction (MI) in CCU follow-up, this new precise intensive care concept was recognized and spread quickly worldwide.¹ Afterward, CCU has been widely used in the follow-up and treatment of patients with other CV emergencies like acute heart failure (HF), life-threatening arrhythmias, and hemodynamically unstable conditions due to other cardiac diseases. Besides, with the development of continuous monitoring systems, specialized nursing services, and advanced treatment modalities, CCUs have been upgraded to more functional facilities.

With the widespread use of dedicated CCUs, countries have shared their data regarding CCU patient characteristics and predictors and incidence of mortality. Reported mortality rates varied between 5% and 13% among countries.²⁻⁴ These differences may arise from different factors, including demographic characteristics, diagnostic and therapeutic tools, and the socioeconomic level of the

ORIGINAL INVESTIGATION

Fatih Kahraman^{1, #} 

İbrahim Ersoy^{2, #} 

Ahmet Seyda Yılmaz^{3, #} 

Adem Atıcı⁴ 

Alpin Mert Tekin⁵ 

Burak Açar⁶ 

Çağlar Kaya⁷ 

Faruk Kara⁸ 

FeYZa Kurt⁹ 

Fulya Avcı Demir¹⁰ 

İdris Buğra Çerik¹¹ 

İshak Yılmaz¹² 

Mehmet Koray Adalı¹³ 

Mehtap Yeni¹⁴ 

Mustafa Beğenç Taşcanov¹⁵ 

Mustafa Yenerçavaş¹⁶ 

Mürsel Şahin¹⁷ 

Ramazan Düz¹⁸ 

Sevil Gülaştı¹⁹ 

Sefa Erdi Ömür²⁰ 

Şahin Topuz²¹ 

Şiho Hidayet²² 

Yücel Kaçmaz²³ 

Nazif Aygül²⁴  , on behalf of

MORCOR-TURK Study Group

¹Department of Cardiology, Kütahya Evliya Çelebi Training and Research Hospital, Kütahya, Turkey

²Department of Cardiology, Faculty of Medicine, Afyonkarahisar Science of Health University, Afyonkarahisar, Turkey

³Department of Cardiology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey

⁴Department of Cardiology, Faculty of Medicine, Medeniyet University, Istanbul, Turkey

⁵Department of Cardiology, Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey

⁶Department of Cardiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey

⁷Department of Cardiology, Edirne Sultan 1. Murat State Hospital, Edirne, Turkey

⁸Department of Cardiology, Ahi Evren Training and Research Hospital, Trabzon, Turkey

⁹Department of Cardiology, Yalova State Hospital, Yalova, Turkey

¹⁰Department of Cardiology, Private Medical Park Hospital, Antalya, Turkey



countries. Thus, comparing mortality rates in CCUs between countries may not be rational due to distinctive opportunities and managing methods. However, it would be very favorable for each country to document the CCU experiences and mortality predictors in line with their circumstances and draw a management algorithm accordingly.

To date, only single-center and limited data on CCU mortality registries have been identified in Turkey, and these studies were designed retrospectively.^{5,6} There is no current multicenter and prospective study examining the mortality rate and its predictors on a national basis in the literature. Therefore, an investigation of MORTality predictors in CORonary Care Units in TURKey (MORCOR-TURK) study was planned to provide up-to-date data on rates and predictors of short and long-term mortality in patients admitted to the CCU with various cardiac emergencies in Turkey.

Moreover, mortality scoring systems have been developed and used to predict in-hospital mortality in intensive care unit (ICU) patients for more than 20 years.^{7,8} Afterward, they have been validated and customized in large sample of medical and surgical ICUs and provided a probability of hospital mortality using logistic regression (LR) models.⁸⁻¹⁰ Coronary care patients were mostly excluded from analysis in these trials. Some recent studies have been published examining the previous and establishing new mortality scoring systems in CCU patients.¹¹⁻¹³ However, there are some limitations in these studies in terms of the number of the centers, including patient population and the study design. Therefore, with this prospective, national, and multicenter study, we planned to develop a new mortality scoring system using LR method in this group of patients.

METHODS

Study Design

The MORCOR-TURK (clinicaltrials.gov NCT05296694) is a multicenter, prospective, cross-sectional, and noninterventional study. It is implemented as a nationwide registry in 50 cardiology centers selected from 7 geographical areas according to their population sample weight, prioritizing the volume of hospitals in each region (Figure 1). It is also the largest registry in Turkey, which provides information on patient characteristics as well as short- and long-term outcomes during CCU follow-up. All consecutive patients admitted to the CCU will be recruited prospectively for 1 month. The names of the centers and researchers are listed in Supplementary File 1.

The first part of the study has a cross-sectional design in which baseline information such as risk factors, demographic data, and cohort characteristics will be assessed. Predictors and risk factors of CV events and in-hospital mortality will be assessed primarily. In the second part of the study, the patients safely discharged from CCU will be followed up by the participating centers for at least 12 months. It will provide information on the predictors of long-term mortality, rehospitalization, and CV events.

Study Population

All consecutive patients admitted to the CCUs in participating centers between 1 and 30 September 2022 will be included in the study. Both genders aged 18 years and older with various cardiac emergencies (acute coronary syndrome (ACS), acute HF, tachyarrhythmias, bradyarrhythmias, myopericarditis, and cardiogenic shock) and those who have signed an informed consent form will be enrolled. Patients meeting the following criteria will be excluded from the study: (1) who do not desire to participate in the study and are

¹¹Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey

¹²Department of Cardiology, Bağcılar Training and Research Hospital, Istanbul, Turkey

¹³Department of Cardiology, Faculty of Medicine, Pamukkale University, Denizli, Turkey

¹⁴Department of Cardiology, Isparta City Hospital, Isparta, Turkey

¹⁵Department of Cardiology, Faculty of Medicine, Harran University, Şanlıurfa, Turkey

¹⁶Department of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey

¹⁷Department of Cardiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

¹⁸Department of Cardiology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey

¹⁹Department of Cardiology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey

²⁰Department of Cardiology, Faculty of Medicine, Gaziosmanpaşa University, Tokat, Turkey

²¹Department of Cardiology, Tekirdağ City Hospital, Tekirdağ, Turkey

²²Department of Cardiology, Faculty of Medicine, İnönü University, Malatya, Turkey

²³Department of Cardiology, Keşan State Hospital, Edirne, Turkey

²⁴Department of Cardiology, Faculty of Medicine, Selçuk University, Konya, Turkey

Corresponding author:

Fatih Kahraman

✉ drfkahraman@gmail.com

Received: November 23, 2022

Accepted: December 23, 2022

Available Online Date: February 23, 2023

Cite this article as: Kahraman F, Ersoy İ, Yılmaz AS, et al. Rationale, design, and methodology of the MORCOR-TURK trial: Predictors of in-hospital MORTality in CORonary care patients in Turkey. *Anatol J Cardiol.* 2023;27(5):258-265.

#First three authors F Kahraman, I Ersoy, and AS Yılmaz contributed equally and shared first authorship.

DOI:10.14744/AnatolJCardiol.2022.2824

HIGHLIGHTS

- Current data on mortality rates and predictors in coronary care unit (CCU) are limited.
- Knowing the main predictors of short- and long-term mortality may improve the clinicians' management of CCU patients.
- New mortality scoring system may help to categorize CCU patients and allow us to distinguish critically ill patients.
- MORCOR-TURK study is expected to contribute to the management of the CCU patients.




Figure 1. Geographic distribution of the MORCOR-TURK study centers in Turkey. MORCOR-TURK, MORtality predictors in CORonary care units in TURKey.

unwilling to sign informed consent, (2) patients admitted to CCU with noncardiac diseases by other disciplines, (3) discharged from CCU within 4 hours due to patient request, (4) those who followed in CCU after elective interventional procedures (percutaneous coronary and peripheral interventions, transcatheter valve interventions, and other cardiac interventions), and (5) patients who arrived at CCU under cardiopulmonary resuscitation (CPR) and did not respond to CPR will also be excluded.

Demographic and clinical characteristics, hemodynamic status and laboratory findings, primary admission diagnoses, in-hospital adverse events, and discharge status will be recorded. All patients will be followed in CCU under the care of cardiologists and will receive standard care of medical and interventional treatment in accordance with current clinical practice guidelines. All medications used during the follow-up and patients' vital signs will be recorded. Adverse events such as arrhythmias (atrial fibrillation [AF], ventricular tachycardia/fibrillation, atrioventricular blocks, etc.), ischemic or hemorrhagic stroke, acute renal failure, minor-major bleeding, and death during in-hospital follow-up will also be recorded. Patients enrolled in the study will not receive any additional medical or interventional treatment due to their participation. The study flow chart is shown in Figure 2.

Center Selection

The main purpose of this study is to demonstrate the descriptive properties, clinical characteristics, and incidence of mortality data of CCU patients in Turkey. Therefore, to ensure adequate geographic diversity according to population densities, we invited centers from 7 geographical regions of Turkey. Fifty of these invited centers having 24-hour follow-up care for CCU patients from all 7 regions accepted to participate in the study. The geographic

distribution of hospitals across the country and the overall profile of the participating CCUs will be representative of the national setting in Turkey.

Prior to patient enrollment, the study coordinators held several meetings about the basic design, methodology, and short- and long-term outcomes. In these meetings, the basic concepts were defined, and then the template of the study form was sent to all participants for review. After participants reviewed the form, 2 online meetings were conducted to receive suggestions and brief participants on the importance, inclusion and exclusion criteria, and the accuracy of the study. A social media platform (WhatsApp group) was set up to ensure the necessary communication before and during the study and to inform and support all participants with questions or problems.

Sample Size and Power Analysis

The study was primarily designed as a descriptive study to find out the incidence and predictors of mortality and was planned to describe the clinical properties of CCU patients in Turkey. However, selecting eligible patients from all over the country would be difficult. Therefore, at least 50 centers representing all geographical regions were determined to reflect the whole country. It was decided to use stratified sampling together with the random sampling method according to the weights of the centers.

The power analysis of the study was performed by GPower 3.1.9.2. (Universitaet Kiel, Germany) software. The test family was chosen as "Exact" and the statistical test as "Proportion: Difference from constant (binomial test, one sample case)" since the mortality rate was given about 10% (5%-13%) in the literature. The effect size was determined using the approximate mortality rate (10%) as proportion P_2 versus $P_1=0.50$. Considering the type-I error rate as 0.05 and the power as 0.95, the effect size was calculated as 0.05.




Figure 2. Flow diagram illustrating patients meeting entry criteria.

Thus, the minimum required sample size was calculated as 1092. As more patients would be better to reflect the whole country to determine the short- and long-term mortality rate in CCU, we planned approximately 3000 patients to be included in the study during this period.

Definitions and Outcomes

The definitions of ACS are based on the guidelines of the European Society of Cardiology. ST-elevation MI is diagnosed when troponin levels are elevated, symptoms consisted of myocardial ischemia and significant ST-elevation in at least two contiguous leads or suspected new left bundle branch block on 12-lead electrocardiogram (ECG). Non-ST-elevation MI is diagnosed when symptoms consisted of myocardial ischemia with no ST-elevation and high troponin levels on 12-lead ECG.

Acute HF is defined as the rapid or gradual onset of symptoms or signs of HF, severe enough to require patients to seek urgent medical attention, resulting in unplanned hospitalization or an emergency department visit.¹⁴ Rapid ventricular rate AF was defined as causing the patient to seek urgent medical attention with or without hemodynamic compromise with irregular R-R intervals on ECG without distinct p waves. Sustained ventricular tachycardia was defined as tachyarrhythmia lasting longer than 30 seconds or hemodynamic instability occurring in less than 30 seconds with wide QRS complex on ECG. Bradyarrhythmia was defined as a heart rate lower than 60 bpm with a rhythm other than sinus rhythm requiring intervention or close follow-up. Cardiogenic shock has been defined as severe impairment in myocardial performance resulting in decreased cardiac

output, end-organ hypoperfusion, and hypoxia; presenting clinically as hypotension refractory to volume resuscitation with end-organ hypoperfusion, cardiogenic shock requires pharmacological or mechanical intervention.¹⁵ Pericarditis and myocarditis were defined as the inflammation of the pericardial layers or myocardium supported by laboratory results and imaging modalities in patients presenting with similar symptoms.

In addition to primary admission diagnoses, we will also record CV risk factors of admitted patients such as a family history of coronary artery disease, smoking status, history of diabetes mellitus, hypertension, hyperlipidemia (HL), chronic kidney disease, peripheral artery disease, and HF. Cardiovascular medications used during admission will also be questioned and recorded (Table 1).

Baseline and Follow-Up Data

All participant centers will collect and record data on a previously prepared and shared "The MORCOR-TURK Study Google Form" online. Basic data to be included in the form will be demographic and clinical characteristics, CV risk factors and primary admission diagnoses, Killip class, basic ECG findings, blood pressure, heart rate, follow-up time in CCU (hours), CV medications on admission, in-hospital, and at discharge, basic echocardiographic findings, biochemical test results, complete blood count, lipid profile, and troponin level. In-hospital and long-term outcomes (1st, 6th, and 12th months) will include death, rehospitalization, AF occurrence, ischemic-hemorrhagic stroke, acute renal failure, major-minor bleeding, and recorded malignant arrhythmias. Adverse event information after hospital discharge

Table 1. Summary of the MORCOR-TURK Survey Questionnaire

Baseline Demographic Characteristics	Admission Complaint and Diagnosis	Treatments	Echocardiographic and Laboratory Measurements	
			Measurements	Events in Hospital
Age	Chief complaint	Prehospital treatment	Echocardiography	Death
Sex			EF	Death type
Height (cm)	• Chest pain	• Acetylsalicylic acid	Valve pathologies	Stroke
Weight (kg)	• Dyspnea	• Other platelets	Laboratory	Atrial fibrillation
Medical history	• Syncope/near syncope	• Oral anticoagulants		VF/VT
• Coronary artery disease	• Palpitation	• Beta-blockers	• Troponin	Mechanical ventilation
• PCI history	• Sudden death	• ACEI/ARB	• Peak troponin	Acute renal failure
• Myocardial infarction history	• Acute ischemic leg pain	• Calcium channel blockers	• Lipids (LDL, HDL, TG)	Bleeding
• Bypass surgery history	Main admission diagnosis	• Statins	• Liver enzymes,	CCU follow-up
• Peripheral artery history	• STEMI	• Proton pump inhibitors	• TSH	
• Atrial fibrillation history	• NSTEMI	In-hospital treatment	• WBC	
• Heart failure history	• USAP	• Acetylsalicylic acid	• Hemoglobin	
• Hypertension	• Acute pulmonary edema	• Other platelets	• Hematocrit	
• Diabetes mellitus	• Decompensated HF	• Low molecular weight heparin	• Platelet count	
• Dyslipidemia	• Arrhythmia	• Positive inotropes	• Creatinine	
• Smoking status	• Cardiac arrest	• Gp IIb/IIIa inhibitors		
• Family history CAD	• Critical limb ischemia	• Thrombolytic treatment		
• Cardiac device	• Complication during intervention	• Invasive treatment		
• Stroke history	Killip class	• Beta-blockers		
• Prior major bleeding history	Admission rhythm	• ACEI/ARB		
• Chronic kidney disease	• Sinus rhythm	• Calcium channel blockers		
• CHA ₂ DS ₂ VASc score	• Atrial fibrillation	• Statins		
	• Other SVTs	• Proton pump inhibitors		
	• AV block	• Others		
	• Ventricular tachycardia			
	• Ventricular fibrillation			
	• Cardiac arrest			
	• Pacemaker rhythm			
	Acute ischemic changes on ECG			
	Systolic blood pressure			
	Diastolic blood pressure			
	Heart rate			
	Saturation			

CAD, coronary artery disease; CCU, critical care unit; HDL, high-density lipoprotein; HF, heart failure; LDL, low-density lipoprotein; TG, triglyceride; TSH, thyroid-stimulating hormone; WBC, white blood cell; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; NSTEMI, Non-ST elevation myocardial infarction; USAP, unstable angina pectoris; SVT, supraventricular tachycardia; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; EF, ejection fraction; VF, ventricular fibrillation; VT, ventricular tachycardia; CCU, coronary care unit.

will be collected in each outpatient clinic control. No extra visits other than routine outpatient visits will be planned. If the patient is lost to follow-up, phone calls, electronic medical records, and a national database system will be used to reach outcomes (Figure 3).

Data Management

All study centers will enter the data into the previously built-up Google forms. All data will be automatically converted to excel spreadsheets and checked for missing or mismatched

data. In case of incompatibility, the coordinators will contact the participants to resolve the problem. After reviewing and completing all shortcomings, the last remaining data will be analyzed and interpreted according to the protocol and design of the study.

Mortality Scoring System

The MORCOR variables will be selected within the first 24-hour admission to CCU. Patients' demographic characteristics including age, gender, admission diagnosis, CV




Figure 3. Timeline of the MORCOR-TURK study. MORCOR-TURK, MORTality predictors in CORonary care units in TURKey.

risk factors, vital signs (heart rate, blood pressure, and oxygen saturation), and laboratory findings (serum creatinine, sodium, potassium, calcium and magnesium levels, glomerular filtration rate, white blood cells, hemoglobin, and platelet levels) will be recorded. Thereafter, all demographic and clinical variables will be tested in LR analysis and crude hazard ratios and 95% confidence intervals will be computed. The variables which were found statistically significant will be added to multivariable LR analysis to provide final model for predicting in-hospital mortality. The mean area under the receiver operating characteristic curve will be used to test the discriminative power of the final model (C-statistic). Moreover, predictive accuracy of the models will be tested separately in large subgroups of the patients such as ACS and acute/decompensated HF.

Ethical Considerations

The study protocol has been reviewed and approved by the Local Ethics Committee (No: 2022/9-422; Date: 05/08/2022). The study will comply with the good clinical practices protocol and Declaration of Helsinki principles. Written informed consent will be obtained from all participants or their relatives.

DISCUSSION

The MORCOR-TURK study will be the largest registry to demonstrate current mortality rates and predictors of CCU patients in Turkey. Furthermore, it will show the incidences of in-hospital adverse events, including acute renal failure, AF occurrence, ischemic/hemorrhagic events, and bleeding in this population. It will also enlighten the independent predictors of long-term mortality in patients discharged from CCU. In addition, it will provide data for building a new CCU mortality score.

The first CCUs were formed in the early 1960s, after the introduction of defibrillation and continuous electrocardiographic monitoring in clinical practice. The most important purpose was to rapidly identify and terminate the perinfarction malignant arrhythmias developing during acute MI.^{16,17} Multiple studies have shown that close follow-up of acute MI patients in CCU has ensured a 15%-20% decline in

in-hospital mortality.¹¹⁸ Furthermore, besides continuous monitoring and trained personnel support, progress in interventional techniques (right heart catheterization, etc.) and echocardiographic imaging have caused favorable prognostic results in all critical cardiac patients. Given these positive results, the importance of CCU in clinical cardiology practice has become indisputable.

However, the patient profile admitted to the CCU has changed over time. In addition to STEMI, patients with more complications such as acute pulmonary edema, decompensated HF, life-threatening arrhythmias and patients with advanced age and high comorbidities have increased in number in CCUs. Katz et al⁴ reported relative change in odds of STEMI was -7% and non-STEMI 13%, while non-ACS diagnosis and interventions increased steadily within the Duke University CCU from 1989 to 2006. Due to the increase in the mortality risks of hospitalized patients in parallel with technological developments and the increase in clinical experience, a negligible decrease was observed in CCU mortality (Supplementary Figure 1).¹⁹

With the evolution in capabilities of CCUs and changes in patient profiles, different countries have shared their CCU experiences and mortality rates. However, most of these data were shared in the 1990s and early 2000s. For example, in a report from Canada, the mortality rate for patients admitted to CCU was 13%; in other reports from Israel, it was 5.4%; and in the United States, 7%-8%.²⁻⁴ Nevertheless, there has not been up-to-date data on the predictors and rates of CCU mortality. Furthermore, although multicenter and national studies have been conducted in Turkey in different patient groups, including AF, ACS, direct oral anticoagulants, drug interactions, and HL, no previous national study has been conducted to investigate the CCU mortality.²⁰⁻²⁵ Therefore, we designed the MORCOR-TURK study to eliminate this deficiency, shed light on the literature, and present the current data of our country in this field.

Risk scores have been established for different patient populations to predict mortality. Especially, different mortality scoring systems such as Acute Physiologic Score and Chronic

Health Evaluation (APACHE), and Simplified Acute Physiology Score (SAPS) have been tested in ICU patients, and they successfully predicted in-hospital mortality.^{26,27} But CCU patients were mostly excluded from prediction analysis of these scoring systems. Besides, different scoring systems such as TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary Events) have been used for mortality prediction in ACS patients.^{28,29} The most recent studies on mortality predictors and new scoring systems in CCU patients were performed by Bagaswoto et al¹¹ and Pramudyo et al.¹² However, these studies are limited due to their single-center and retrospective design. Furthermore, the latter one included only ACS patients. Another recent study in this area was conducted by Blatter et al.¹³ Despite its prospective design, this study included only cardiac arrest patients in a single center. Moreover, in this study, instead of forming a new scoring system, previously accepted risk scores were compared to each other. Therefore, with the current multi-center study, we are planning to contribute to the literature by generating a new scoring system for all CCU patients.

Study Limitations

The results of this study should be interpreted with some caution because of several limitations. The first limitation is that we did not include all CCU-capable centers to analyze the data. But since the centers were selected according to the regional distribution of Turkey, it is unlikely to adversely affect the results. The second limitation is that the interventional facilities of the centers and the skills and experience of the operators may affect the results of the procedures and therefore the mortality rates. However, in this study, we aimed to reveal the national data of Turkey, not the differences between the centers and operators. Final limitation is an additional uncontrolled factor is a possibility that the study has a cross-sectional observational design that could affect bias and confounding. Notwithstanding these limitations, this study offers insight into current data on mortality predictors of CCU in Turkey.

CONCLUSION

The findings of the MORCOR-TURK study will have several contributions to the current literature. First, it will give the current CCU mortality data in Turkey. Furthermore, it will help to enlighten the most important predictors of mortality in CCU. Thus, it will increase our awareness of taking precautions against the risk factors. Second, it will give information about the distribution of each diagnosis. Moreover, subgroup analyses will show the highest and lowest mortality rates according to the diagnoses. Third, with the help of this national data, we will be able to contribute to the literature with a new scoring system about mortality.

Ethics Committee Approval: Study has been approved by the Ethics Committee of Afyonkarahisar University of Health Sciences, Afyon, Turkey (No: 2022/9-422; Date: 05/08/2022).

Informed Consent: Written informed consent was obtained from all participants who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: According to the International Committee of Medical Journal Editors (ICMJE), all authors of this article meet the authorship criteria. In addition, all authors have seen and approved the submitted and published manuscript.

Acknowledgments: MORCOR-TURK is an investigator-initiated study. There were no other contributors to the article than the authors. Therefore, this article did not require receiving specific grants from funding agencies in public, commercial or not-for-profit sectors.

Declaration of Interests: The authors report no conflicts of interest in this work.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.


REFERENCES

1. Killip Iii T, Kimball JT, York N. Treatment of myocardial infarction in a Coronary Care Unit A two year experience with 250 patients*. *Am J Cardiol.* 1967;20(4):457-464. [CrossRef]
2. Rotstein Z, Mandelzweig L, Lavi B, Eldar M, Gottlieb S, Hod H. Does the coronary care unit improve prognosis of patients with acute myocardial infarction? A thrombolytic era study. *Eur Heart J.* 1999;20(11):813-818. [CrossRef]
3. Teskey RJ, Calvin JE, McPhail I. Disease severity in the coronary care unit. *Chest.* 1991;100(6):1637-1642. [CrossRef]
4. Katz JN, Shah BR, Volz EM, et al. Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. *Crit Care Med.* 2010;38(2):375-381. [CrossRef]
5. Doğan S, Dursun H, Can H, Ellidokuz H, Kaya D. Long-term assessment of coronary care unit patient profile and outcomes: analyses of the 12-years patient records. *Turk J Med Sci.* 2016;46(3):801-806. [CrossRef]
6. Kūlahçiođlu Ő, Acar RD, İzci S, et al. Characteristics and gender-related differences of patients admitted to a large intensive Cardiac Care Unit: A single-center experience with over 55 000 patients. *Turk Kardiyol Dern Ars.* 2022;50(6):431-437. [CrossRef]
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Apache II: a severity of disease classification system. *Crit Care Med.* 1985;13(10):818-829. [CrossRef]
8. le Gall JR, Lemeshow S. Simplified acute physiology score (SAPS II) based on a European / North American multicenter study. *JAMA.* 1993;270(24):2957-2963.
9. Moreno R, Morais P, Morais, P. Outcome prediction in intensive care: results of a prospective, multicentre, Portuguese study. *Intensive Care Med.* 1997;23.
10. Beck DH, Smith GB, Pappachan JV v., Millar B. External validation of the SAPS II, Apache II and Apache III prognostic models in South England: a multicentre study. *Intensive Care Med.* 2003;29(2):249-256. [CrossRef]
11. Bagaswoto HP, Taufiq N, Setianto BY. A simplified risk scoring system to predict mortality in cardiovascular Intensive Care Unit. *Cardiol Res.* 2019;10(4):216-222. [CrossRef]
12. Pramudyo M, Bijaksana TL, Yahya AF, Putra ICS. Novel scoring system based on clinical examination for prediction of in-hospital mortality in acute coronary syndrome patients: a retrospective cohort study. *Open Heart.* 2022;9(2):e002095. [CrossRef]
13. Blatter R, Amacher SA, Bohren C, et al. Comparison of different clinical risk scores to predict long-term survival and neurological outcome in adults after cardiac arrest: results from a prospective cohort study. *Ann Intensive Care.* 2022;12(1):77. [CrossRef]

14. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599-3726. [\[CrossRef\]](#)
15. van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. *Circulation*. 2017;136(16):e232-e268. [\[CrossRef\]](#)
16. Julian DG. The history of coronary care units. *Br Heart J*. 1987; 57(6):497-502. [\[CrossRef\]](#)
17. Julian DG. Treatment of cardiac arrest in acute myocardial ischaemia and infarction. *Lancet*. 1961;2(7207):840-844. [\[CrossRef\]](#)
18. Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. *Lancet*. 1998;352(9142):1771-1774. [\[CrossRef\]](#)
19. Morrow DA, Fang JC, Fintel DJ, et al. Evolution of critical care cardiology: transformation of the cardiovascular Intensive Care Unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. *Circulation*. 2012;126(11):1408-1428. [\[CrossRef\]](#)
20. Kayıkçıoğlu M, Tokgözoğlu L, Kılıçkap M, et al. Data on prevalence of dyslipidemia and lipid values in Turkey: systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors. *Turk Kardiyol Dern Ars*. 2018;46(7): 556-574. [\[CrossRef\]](#)
21. Erol MK, Kayıkçıoğlu M, Kılıçkap M. Rationale and design of the Turkish acute myocardial infarction registry: the Turkmi study. *Anatol J Cardiol*. 2020;23(3):169-175. [\[CrossRef\]](#)
22. Güzel T, Aktan A, Kılıç R, et al. Oral anticoagulant use and long-term follow-up results in patients with non-valvular atrial fibrillation in Turkey AFTER-2 study. *Anatol J Cardiol*. 2022;26(7): 567-576. [\[CrossRef\]](#)
23. Hayıroğlu Mİ, Keskin M, Uzun AO, et al. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock. *Heart Lung Circ*. 2019;28(2):237-244. [\[CrossRef\]](#)
24. Altay S, Yıldırım Türk Ö, Çakmak HA, et al. New oral anti-coagulants-TURKey (NOAC-TURK): multicenter cross-sectional study. *Anatol J Cardiol*. 2017;17(5):353-361. [\[CrossRef\]](#)
25. Özlek E, Çekiç EG, Özlek B, et al. Rationale, design, and methodology of the EPIC (Epidemiology of Polypharmacy and Potential drug-drug Interactions in Elderly Cardiac Outpatients) study. *Turk Kardiyol Dern Ars*. 2019;47(5):391-398. [\[CrossRef\]](#)
26. Katsaragakis S, Papadimitropoulos K, Antonakis P, Strergopoulos S, Konstadoulakis MM, Andrulakis G. Comparison of Acute Physiology and Chronic Health Evaluation II (Apache II) and simplified Acute Physiology Score II (SAPS II) scoring systems in a single Greek intensive care unit. *Crit Care Med*. 2000;28(2): 426-432. [\[CrossRef\]](#)
27. Moreno R, Miranda DR, Fidler V, van Schilfgarde R. Evaluation of two outcome prediction models on an independent database. *Crit Care Med*. 1998;26(1):50-61. [\[CrossRef\]](#)
28. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA*. 2000;284(7): 835-842. [\[CrossRef\]](#)
29. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. *Arch Intern Med*. 2003;163(19):2345-2353. [\[CrossRef\]](#)

Supplementary File 1

MORCOR-TURK Study Group: Adnan Menderes University, Sevil Gülaştı; Afyonkarahisar Health Sciences University, İbrahim Ersoy; Afyon State Hospital, Fatih Oğuz; Ahi Evren Research and Training Hospital, Faruk Kara; Aksaray University, Murat Gül; Alanya Alaaddin Keykubat University, Can Ramazan Öncel; Amasya University, Ömer Kertmen; Ankara University, Seyhmus Atan, Başar Candemir; Antalya Medicalpark Hospital, Fulya Avcı Demir; Bağcılar Research and Training Hospital, İrfan Şahin, İshak Yılmaz; Balıkesir University, Özgen Şafak; Cerrahpaşa School of Medicine, Alpin Mert Tekin; Cumhuriyet University, İdris Buğra Çerik; Çanakkale 18 Mart University, Uğur Küçük; Dışkapı Research and Training Hospital, Meltem Altınsoy; Dicle University, Mehmet Özbek; Edirne Sultan 1. Murat State Hospital, Çağlar Kaya; Erciyes University, Şaban Keleş; Ersin Arslan Research and Training Hospital, Emin Erdem Kaya; Eskişehir City Hospital, Mehmet Özgeyik; Eskişehir Osmangazi University, Gurbet Özge Mert; Göztepe Research and Training Hospital, Adem Atıcı; Giresun University, Ertan Aydın; Harran University, Mustafa Beğenç Taşçanov; Isparta City Hospital, Mehtap Yeni; İnönü University, Şiho Hidayet; İstanbul Cardiology Institute, Aybike Gül Taşdelen, Hasan Ali Barman; Kafkas University, Muammer Karakayalı; Kahramanmaraş Sütçü İmam University, Murat Kerkütlüoğlu; Karadeniz Technical University, Mürsel Şahin; Karaman Research and Training Hospital, Oğuz Kılıç; Keşan State Hospital, Yücel Kaçmaz; Kocaeli University, Burak Açar; Kütahya Evliya Çelebi Research nad Training Hospital, Fatih Kahraman, Mevlüt Demir; Ordu University, Fatih Akkaya, Mustafa Yenerçağ; Osmaniye State Hospital, Muhammed Erkam Cengil; Pamukkale University, Mehmet Koray Adalı; Recep Tayyip Erdoğan University, Ahmet Seyda Yılmaz, Muhammed Mürsel Öğütveren; Rize State Hospital, İsmail Barkın Işık; Samsun Research and Training Hospital, Melisa Uçar; Selçuk University, Nazif Aygül; Siirt Research and Training Hospital, Yunus Emre Yavuz; Tekirdağ City Hospital, Şahin Topuz; Tokat Gaziosmanpaşa University, Sefa Erdi Ömür; Trakya University, Gökay Taylan; Uşak Research and Training Hospital, Ferhat Dindaş; Van Research and Training Hospital, Ömer Kümet; Van Yüzüncü Yıl University, Ramazan Düz, Muhammed Kaya; Yalova State Hospital, Feyza Kurt; Yozgat City Hospital, Serdar Gökhan Nurkoç.



Supplementary Figure 1. Clinical and technological change of the coronary care unit.